Back to Report Store Home

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • Published: Apr-2018
  • Report Code: GBIHC029IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 3: Number of Products under Development for Dementia

Figure 4: Number of Products under Development by Companies, Dementia

Figure 5: Number of Products under Development by Universities/Institutes, Dementia

Figure 6: Number of Products under Development for Mild Cognitive Impairment

Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment

Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment

Figure 9: Number of Products under Development for Alzheimer's Disease

Figure 10: Number of Products under Development by Companies, Alzheimer's Disease

Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease

Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 20: Number of Products by Top 10 Targets, Dementia

Figure 21: Number of Products by Stage and Top 10 Targets, Dementia

Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia

Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia

Figure 24: Number of Products by Top 10 Routes of Administration, Dementia

Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia

Figure 26: Number of Products by Top 10 Molecule Types, Dementia

Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia

Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment

Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment

Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment

Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment

Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment

Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment

Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease

Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease

Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease

Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease

Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease

Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards